Neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy, covering 2024-11-07 to 2024-11-07. Get the full timeline:
Most recent: Clinical Trial Update: Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors [EARLY_Phase 1]